MRNA- a vaccine biotechnology stock LONG

2월 27일

MRNA focuses on vaccine research and development and we are in the flu season an COVID is

lurking in the shadows and trying to make a comback. It had an excellent earnings report and

forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored

VWAP and is at the level of the first upper VWAP while in side the high volume area of the

volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing

position here and again the next time I see a dip on the 15-30-minute chart. I look forward

to take a piece out of the position after the next earnings report in about 75 days. I have an

alert for relative volume when the running mean is exceeded on the 30 minute chart which

notify me to take a look at the chart. This is illustrated on this longer time frame chart about

the days around earnings but occurs from time to time from other events. As an aside, if NVAX

gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be

the leading candidate to do a takeover, friendly or otherwise.